The effectiveness of phytosomal curcumin on clinical and laboratory parameters of patients with multiple trauma admitted to the intensive care unit: a double-blind randomized placebo-controlled trial.
Critically ill patients
Curcumin
ICU
Inflammation
Phytomedicine
Trauma
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
17 Sep 2024
17 Sep 2024
Historique:
received:
17
12
2023
accepted:
10
09
2024
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
17
9
2024
Statut:
epublish
Résumé
Multiple trauma has serious complications, which increases the risk of morbidity and mortality in the patients. This study aimed to evaluate the impact of supplementation with phytosomal curcumin on clinical and laboratory factors in critically ill patients with multiple trauma. In this double-blind trial, 53 patients with multiple trauma, who were admitted to the intensive care unit (ICU) were randomized to receive either 2 capsules, each capsule containing 250 mg phytosomal (a total of 500 mg daily) as an intervention group or 2 identical capsules (placebo capsules), each containing 250 mg maltodextrin for 7 days. Clinical and laboratory were parameters assessed before and after the intervention. After seven days of intervention, the mean increase from baseline in the Glasgow coma scale (GCS) score was significantly higher in the curcumin compared with the placebo group (P-value: 0.028), while the reduction in the APACHE-II score in the curcumin group was greater than that the placebo group in a marginally non-significant fashion (P-value: 0.055). Serum total bilirubin (P-value: 0.036) and quantitative C-reactive protein (CRP) (P-value: 0.044) levels significantly decreased while potassium (P-value: 0.01) significantly increased in the curcumin compared with the placebo group. Moreover, supplementation with phytosomal curcumin significantly increased platelet count (P-value: 0.024) as compared with placebo. The 28-day mortality rate was 7.7% (n: 2 patients) and 3.7% (n: 1 patients) in the placebo and curcumin groups, respectively (P-value > 0.05). Phytosomal curcumin had beneficial effects on several clinical and laboratory factors including GCS, APACHEII, serum total bilirubin, CRP, and platelet count in ICU-admitted patients with multiple trauma. IRCT20090306001747N1, Available on: https://www.irct.ir/trial/52692 . The first registration date was 12/01/2021.
Sections du résumé
BACKGROUND
BACKGROUND
Multiple trauma has serious complications, which increases the risk of morbidity and mortality in the patients. This study aimed to evaluate the impact of supplementation with phytosomal curcumin on clinical and laboratory factors in critically ill patients with multiple trauma.
METHODS
METHODS
In this double-blind trial, 53 patients with multiple trauma, who were admitted to the intensive care unit (ICU) were randomized to receive either 2 capsules, each capsule containing 250 mg phytosomal (a total of 500 mg daily) as an intervention group or 2 identical capsules (placebo capsules), each containing 250 mg maltodextrin for 7 days. Clinical and laboratory were parameters assessed before and after the intervention.
RESULTS
RESULTS
After seven days of intervention, the mean increase from baseline in the Glasgow coma scale (GCS) score was significantly higher in the curcumin compared with the placebo group (P-value: 0.028), while the reduction in the APACHE-II score in the curcumin group was greater than that the placebo group in a marginally non-significant fashion (P-value: 0.055). Serum total bilirubin (P-value: 0.036) and quantitative C-reactive protein (CRP) (P-value: 0.044) levels significantly decreased while potassium (P-value: 0.01) significantly increased in the curcumin compared with the placebo group. Moreover, supplementation with phytosomal curcumin significantly increased platelet count (P-value: 0.024) as compared with placebo. The 28-day mortality rate was 7.7% (n: 2 patients) and 3.7% (n: 1 patients) in the placebo and curcumin groups, respectively (P-value > 0.05).
CONCLUSION
CONCLUSIONS
Phytosomal curcumin had beneficial effects on several clinical and laboratory factors including GCS, APACHEII, serum total bilirubin, CRP, and platelet count in ICU-admitted patients with multiple trauma.
TRIAL REGISTRATION
BACKGROUND
IRCT20090306001747N1, Available on: https://www.irct.ir/trial/52692 . The first registration date was 12/01/2021.
Identifiants
pubmed: 39289667
doi: 10.1186/s12906-024-04639-3
pii: 10.1186/s12906-024-04639-3
doi:
Substances chimiques
Curcumin
IT942ZTH98
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
335Subventions
Organisme : Isfahan University of Medical Sciences
ID : 199374
Informations de copyright
© 2024. The Author(s).
Références
Scott SG, Scholten JD, Latlief GA, Humayun F, Belanger HG, Vanderploeg RD. Chap. 136 - Polytrauma Rehabilitation. In: Essentials of Physical Medicine and Rehabilitation (Second Edition). edn. Edited by Frontera WR, Silver JK, Rizzo TD. Philadelphia: W.B. Saunders; 2008: 787–791.
Soucacos PN, Johnson EO. Multiple Trauma. In: Encyclopedia of Stress (Second Edition). edn. Edited by Fink G. New York: Academic Press; 2007: 795–800.
Lord JM, Midwinter MJ, Chen Y-F, Belli A, Brohi K, Kovacs EJ, Koenderman L, Kubes P, Lilford RJ. The systemic immune response to trauma: an overview of pathophysiology and treatment. Lancet. 2014;384(9952):1455–65.
pubmed: 25390327
pmcid: 4729362
doi: 10.1016/S0140-6736(14)60687-5
Pape HC, Moore EE, McKinley T, Sauaia A. Pathophysiology in patients with polytrauma. Injury. 2022;53(7):2400–12.
pubmed: 35577600
doi: 10.1016/j.injury.2022.04.009
Kotha RR, Luthria DL. Curcumin: Biological, Pharmaceutical, Nutraceutical, and Analytical aspects. Molecules 2019, 24(16).
Bagheri H, Ghasemi F, Barreto GE, Rafiee R, Sathyapalan T, Sahebkar A. Effects of curcumin on mitochondria in neurodegenerative diseases. BioFactors. 2020;46(1):5–20.
pubmed: 31580521
doi: 10.1002/biof.1566
Marjaneh RM, Rahmani F, Hassanian SM, Rezaei N, Hashemzehi M, Bahrami A, Ariakia F, Fiuji H, Sahebkar A, Avan A, et al. Phytosomal curcumin inhibits tumor growth in colitis-associated colorectal cancer. J Cell Physiol. 2018;233(10):6785–98.
pubmed: 29737515
doi: 10.1002/jcp.26538
Panahi Y, Fazlolahzadeh O, Atkin SL, Majeed M, Butler AE, Johnston TP, Sahebkar A. Evidence of curcumin and curcumin analogue effects in skin diseases: a narrative review. J Cell Physiol. 2019;234(2):1165–78.
pubmed: 30073647
doi: 10.1002/jcp.27096
El-Saadony MT, Yang T, Korma SA, Sitohy M, Abd El-Mageed TA, Selim S, Al Jaouni SK, Salem HM, Mahmmod Y, Soliman SM, et al. Impacts of turmeric and its principal bioactive curcumin on human health: Pharmaceutical, medicinal, and food applications: a comprehensive review. Front Nutr. 2022;9:1040259.
pubmed: 36712505
doi: 10.3389/fnut.2022.1040259
Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195–218.
pubmed: 23143785
doi: 10.1208/s12248-012-9432-8
Mohseni M, Sahebkar A, Askari G, Johnston TP, Alikiaii B, Bagherniya M. The clinical use of curcumin on neurological disorders: an updated systematic review of clinical trials. Phytother Res. 2021;35(12):6862–82.
pubmed: 34528307
doi: 10.1002/ptr.7273
Mahdavi A, Moradi S, Askari G, Iraj B, Sathyapalan T, Guest PC, Bagherniya M, Sahebkar A. Effect of Curcumin on Glycemic Control in patients with type 2 diabetes: a systematic review of Randomized clinical trials. Adv Exp Med Biol. 2021;1291:139–49.
pubmed: 34331688
doi: 10.1007/978-3-030-56153-6_8
Alikiaii B, Bagherniya M, Askari G, Sathyapalan T, Sahebkar A. Evaluation of the effect of curcumin on pneumonia: a systematic review of preclinical studies. Phytother Res. 2021;35(4):1939–52.
pubmed: 33155336
doi: 10.1002/ptr.6939
Alikiaii B, Bagherniya M, Askari G, Johnston TP, Sahebkar A. The role of phytochemicals in sepsis: a mechanistic and therapeutic perspective. BioFactors. 2021;47(1):19–40.
pubmed: 33217777
doi: 10.1002/biof.1694
Heidari H, Bagherniya M, Majeed M, Sathyapalan T, Jamialahmadi T, Sahebkar A. Curcumin-piperine co-supplementation and human health: a comprehensive review of preclinical and clinical studies. Phytother Res 2023.
Hassanizadeh S, Shojaei M, Bagherniya M, Orekhov AN, Sahebkar A. Effect of nano-curcumin on various diseases: a comprehensive review of clinical trials. BioFactors 2023.
Heidari Z, Daei M, Boozari M, Jamialahmadi T, Sahebkar A. Curcumin supplementation in pediatric patients: a systematic review of current clinical evidence. Phytother Res. 2022;36(4):1442–58.
pubmed: 34904764
doi: 10.1002/ptr.7350
Karimi A, Naeini F, Niazkar HR, Tutunchi H, Musazadeh V, Mahmoodpoor A, Asghariazar V, Mobasseri M, Tarighat-Esfanjani A. Nano-Curcumin supplementation in critically ill patients with sepsis: a randomized clinical trial investigating the inflammatory biomarkers, oxidative stress indices, endothelial function, clinical outcomes and nutritional status. Food Funct. 2022;13(12):6596–612.
pubmed: 35621073
doi: 10.1039/D1FO03746C
Karimi A, Pourreza S, Vajdi M, Mahmoodpoor A, Sanaie S, Karimi M, Tarighat-Esfanjani A. Evaluating the effects of curcumin nanomicelles on clinical outcome and cellular immune responses in critically ill sepsis patients: a randomized, double-blind, and placebo-controlled trial. Front Nutr. 2022;9:1037861.
pubmed: 36562037
pmcid: 9763722
doi: 10.3389/fnut.2022.1037861
Zahedi H, Hosseinzadeh-Attar MJ, Shadnoush M, Sahebkar A, Barkhidarian B, Sadeghi O, Najafi A, Hosseini S, Qorbani M, Ahmadi A, et al. Effects of curcuminoids on inflammatory and oxidative stress biomarkers and clinical outcomes in critically ill patients: a randomized double-blind placebo-controlled trial. Phytother Res. 2021;35(8):4605–15.
pubmed: 34080237
doi: 10.1002/ptr.7179
Khayatan D, Razavi SM, Arab ZN, Niknejad AH, Nouri K, Momtaz S, Gumpricht E, Jamialahmadi T, Abdolghaffari AH, Barreto GE et al. Protective effects of curcumin against traumatic brain injury. Biomed Pharmacotherapy 2022, 154.
Allam AN, Komeil IA, Abdallah OY. Curcumin phytosomal softgel formulation: development, optimization and physicochemical characterization. Acta Pharm. 2015;65(3):285–97.
pubmed: 26431106
doi: 10.1515/acph-2015-0029
Lopresti AL. The problem of curcumin and its bioavailability: could its gastrointestinal influence contribute to its overall health-enhancing effects? Adv Nutr. 2018;9(1):41–50.
pubmed: 29438458
pmcid: 6333932
doi: 10.1093/advances/nmx011
Ma Z, Wang N, He H, Tang X. Pharmaceutical strategies of improving oral systemic bioavailability of curcumin for clinical application. J Controlled Release: Official J Controlled Release Soc. 2019;316:359–80.
doi: 10.1016/j.jconrel.2019.10.053
Mirzaei H, Shakeri A, Rashidi B, Jalili A, Banikazemi Z, Sahebkar A. Phytosomal curcumin: a review of pharmacokinetic, experimental and clinical studies. Biomed Pharmacother. 2017;85:102–12.
pubmed: 27930973
doi: 10.1016/j.biopha.2016.11.098
Glade MJ, Smith K. Phosphatidylserine and the human brain. Nutrition. 2015;31(6):781–6.
pubmed: 25933483
doi: 10.1016/j.nut.2014.10.014
Marczylo TH, Steward WP, Gescher AJ. Rapid analysis of curcumin and curcumin metabolites in rat biomatrices using a novel ultraperformance liquid chromatography (UPLC) method. J Agric Food Chem. 2009;57(3):797–803.
pubmed: 19152267
doi: 10.1021/jf803038f
Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol. 2007;60:171–7.
pubmed: 17051370
doi: 10.1007/s00280-006-0355-x
Zahedi H, Hosseinzadeh-Attar MJ, Shadnoush M, Sahebkar A, Barkhidarian B, Sadeghi O, Najafi A, Hosseini S, Qorbani M, Ahmadi A. Effects of curcuminoids on inflammatory and oxidative stress biomarkers and clinical outcomes in critically ill patients: a randomized double‐blind placebo‐controlled trial. Phytother Res. 2021;35(8):4605–15.
pubmed: 34080237
doi: 10.1002/ptr.7179
Shojaei M, Sahebkar A, Khorvash F, Fallahpour S, Askari G, Bagherniya M. The effects of phytosomal curcumin supplementation on clinical symptoms, and inflammatory and oxidative stress biomarkers in patients with migraine: a protocol for a randomized double-blind placebo-controlled trial. Avicenna J Phytomedicine. 2023;13(1):45–57.
Wu A, Ying Z, Schubert D, Gomez-Pinilla F. Brain and spinal cord interaction: a dietary curcumin derivative counteracts locomotor and cognitive deficits after brain trauma. Neurorehabilit Neural Repair. 2011;25(4):332–42.
doi: 10.1177/1545968310397706
Vahdat M, Hosseini SA, Soltani F, Cheraghian B, Namjoonia M. The effects of taurine supplementation on inflammatory markers and clinical outcomes in patients with traumatic brain injury: a double-blind randomized controlled trial. Nutr J. 2021;20(1):53.
pubmed: 34103066
pmcid: 8186362
doi: 10.1186/s12937-021-00712-6
Wu A, Ying Z, Gomez-Pinilla F. Dietary curcumin counteracts the outcome of traumatic brain injury on oxidative stress, synaptic plasticity, and cognition. Exp Neurol. 2006;197(2):309–17.
pubmed: 16364299
doi: 10.1016/j.expneurol.2005.09.004
Kahkhaie KR, Mirhosseini A, Aliabadi A, Mohammadi A, Mousavi MJ, Haftcheshmeh SM, Sathyapalan T, Sahebkar A. Curcumin: a modulator of inflammatory signaling pathways in the immune system. Inflammopharmacology. 2019;27(5):885–900.
pubmed: 31140036
doi: 10.1007/s10787-019-00607-3
Mohammadi A, Blesso CN, Barreto GE, Banach M, Majeed M, Sahebkar A. Macrophage plasticity, polarization and function in response to curcumin, a diet-derived polyphenol, as an immunomodulatory agent. J Nutr Biochem. 2019;66:1–16.
pubmed: 30660832
doi: 10.1016/j.jnutbio.2018.12.005
Shafabakhsh R, Pourhanifeh MH, Mirzaei HR, Sahebkar A, Asemi Z, Mirzaei H. Targeting regulatory T cells by curcumin: a potential for cancer immunotherapy. Pharmacol Res 2019, 147.
Panahi Y, Ghanei M, Hajhashemi A, Sahebkar A. Effects of curcuminoids-Piperine combination on systemic oxidative stress, clinical symptoms and quality of life in subjects with chronic pulmonary complications due to Sulfur Mustard: a Randomized Controlled Trial. J Diet Supplements. 2016;13(1):93–105.
doi: 10.3109/19390211.2014.952865
Ahmadi A, Jamialahmadi T, Sahebkar A. Polyphenols and atherosclerosis: a critical review of clinical effects on LDL oxidation. Pharmacol Res. 2022;184:106414.
pubmed: 36028188
doi: 10.1016/j.phrs.2022.106414
Dehzad MJ, Ghalandari H, Nouri M, Askarpour M. Antioxidant and anti-inflammatory effects of curcumin/turmeric supplementation in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. Cytokine. 2023;164:156144.
pubmed: 36804260
doi: 10.1016/j.cyto.2023.156144
Sabir S, Umer N, Shoaib M, Zulfiqar S. Correlation of interleukin-10 with Glasgow coma scale in patients of stroke. Pakistan J Med Health Sci. 2016;10(1):63–5.
Ali Hosseinian S, Mehrzad J, Reza Mirhafez S, Saeidi J, Zhiani R, Sahebkar A. Evaluation of the effect of phytosomal curcuminoids on oxidative stress and inflammatory markers in NAFLD: a randomized double-blind placebo-controlled trial. J Funct Foods. 2022;96:105202.
doi: 10.1016/j.jff.2022.105202
Wongcharoen W, Phrommintikul A. The protective role of curcumin in cardiovascular diseases. Int J Cardiol. 2009;133(2):145–51.
pubmed: 19233493
doi: 10.1016/j.ijcard.2009.01.073
Cicero AFG, Sahebkar A, Fogacci F, Bove M, Giovannini M, Borghi C. Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial. Eur J Nutr. 2020;59(2):477–83.
pubmed: 30796508
doi: 10.1007/s00394-019-01916-7
Zhang D-w, Fu M, Gao S-H, Liu J-L. Curcumin and diabetes: a systematic review. Evidence-Based Complement Altern Med. 2013;2013:636053.
doi: 10.1155/2013/636053
Meghana K, Sanjeev G, Ramesh B. Curcumin prevents streptozotocin-induced islet damage by scavenging free radicals: a prophylactic and protective role. Eur J Pharmacol. 2007;577(1–3):183–91.
pubmed: 17900558
doi: 10.1016/j.ejphar.2007.09.002
Best L, Elliott AC, Brown PD. Curcumin induces electrical activity in rat pancreatic β-cells by activating the volume-regulated anion channel. Biochem Pharmacol. 2007;73(11):1768–75.
pubmed: 17382910
doi: 10.1016/j.bcp.2007.02.006
Khalooghi K, Hashemi S, Mehraban N, Amiri P, Bazzaz JT, Larijani B, Amoli MM. In vitro modulation of TCF7L2 gene expression in human pancreatic cells. Mol Biol Rep. 2009;36:2329–32.
pubmed: 19156536
doi: 10.1007/s11033-009-9452-3
Yan Y, Klein R, Heiss G, Girman CJ, Lange EM, Klein BE, Rose KM, Boerwinkle E, Pankow JS, Brancati FL. The transcription factor 7-like 2 (TCF7L2) polymorphism may be associated with focal arteriolar narrowing in caucasians with hypertension or without diabetes: the ARIC Study. BMC Endocr Disorders. 2010;10:1–10.
doi: 10.1186/1472-6823-10-9
Gong Z, Zhou J, Li H, Gao Y, Xu C, Zhao S, Chen Y, Cai W, Wu J. Curcumin suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. Mol Nutr Food Res. 2015;59(11):2132–42.
pubmed: 26250869
doi: 10.1002/mnfr.201500316
Mirhafez SR, Azimi-Nezhad M, Dehabeh M, Hariri M, Naderan RD, Movahedi A, Abdalla M, Sathyapalan T, Sahebkar A. The effect of curcumin phytosome on the treatment of patients with non-alcoholic fatty liver disease: a double-blind, randomized, placebo-controlled trial. Pharmacol Prop Plant-Derived Nat Prod Implications Hum Health 2021:25–35.
Al-Kahtani M, Abdel-Daim MM, Sayed AA, El-Kott A, Morsy K. Curcumin phytosome modulates aluminum-induced hepatotoxicity via regulation of antioxidant, Bcl-2, and caspase-3 in rats. Environ Sci Pollut Res. 2020;27(17):21977–85.
doi: 10.1007/s11356-020-08636-0
Swamy AV, Gulliaya S, Thippeswamy A, Koti BC, Manjula DV. Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats. Indian J Pharmacol. 2012;44(1):73.
pubmed: 22345874
pmcid: 3271544
doi: 10.4103/0253-7613.91871
Gorabi AM, Abbasifard M, Imani D, Aslani S, Razi B, Alizadeh S, Bagheri-Hosseinabadi Z, Sathyapalan T, Sahebkar A. Effect of curcumin on C-reactive protein as a biomarker of systemic inflammation: an updated meta-analysis of randomized controlled trials. Phytother Res. 2022;36(1):85–97.
pubmed: 34586711
doi: 10.1002/ptr.7284
Panahi Y, Hosseini MS, Khalili N, Naimi E, Majeed M, Sahebkar A. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: a randomized controlled trial and an updated meta-analysis. Clin Nutr. 2015;34(6):1101–8.
pubmed: 25618800
doi: 10.1016/j.clnu.2014.12.019
Askari G, Bagherniya M, Kiani Z, Alikiaii B, Mirjalili M, Shojaei M, Hassanizadeh S, Vajdi M, Feizi A, Majeed M, et al. Evaluation of Curcumin-Piperine supplementation in COVID-19 patients admitted to the Intensive Care: a Double-Blind, randomized controlled trial. Adv Exp Med Biol. 2023;1412:413–26.
pubmed: 37378780
doi: 10.1007/978-3-031-28012-2_22
Karimi A, Mahmoodpoor A, Kooshki F, Niazkar HR, Shoorei H, Tarighat-Esfanjani A. Effects of nanocurcumin on inflammatory factors and clinical outcomes in critically ill patients with sepsis: a pilot randomized clinical trial. Eur J Integr Med. 2020;36:101122.
doi: 10.1016/j.eujim.2020.101122